Skip to main content
OpenTrials
Completed

NCT Number: NCT04461353

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

This study is 'A Randomized Phase 1 Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers.' The primary objectives are as follows:

* To assess the safety and tolerability of AHCQ administered as a single dose by oral inhalation in healthy individuals at escalating doses until either the maximum tolerated dose (MTD) is identified or 1 mL of a 50 mg/mL solution is administered. * To determine the recommended Phase 2a dose (RP2D).

Secondary objectives:

• To characterize pharmacokinetics (PK) of single dose AHCQ in healthy individuals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

The Rockefeller University

New York, 10065, United States

About this study

Study Design:

This is a randomized, double-blind placebo-controlled Phase 1 single-dose dose-escalation study to assess the safety, tolerability and PK of oral inhalation of AHCQ in healthy participants.

Escalating single doses of AHCQ will be studied in healthy participants. The study drug will be administered by inhalation through the mouth, and participants will be encouraged to exhale through the nose. The study drug, AHCQ, will be administered starting at an initial dose of 20 mg (Cohort A1, 1 mL of 20 mg/mL AHCQ solution) with a proposed subsequent doses of 50 mg (Cohort A2, 1 mL of 50 mg/mL AHCQ).

Number of Participants (Planned):

Two dose levels are planned to be evaluated. Each cohort will comprise 8 participants (6 active, 2 placebo). Therefore, 16 participants will initially be planned to be enrolled in the study. Additional participants may be enrolled if one or more enrolled participants do not complete the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to give written informed consent.
  • Males or females aged ≥18 years old.
  • Good general health as determined by no acute illness and no clinically significant abnormal findings on medical history, vital signs, laboratory tests, or physical examination at screening that, in the opinion of the PI, would interfere with study drug administration, jeopardize the safety of the study participant, or impact the validity of the study results; participants with stable chronic illness are allowed at the discretion of the PI.
  • An interpretable 12-lead ECG with a corrected QT (QTc) interval ≤450 ms, according to Bazett's formula, without evidence of clinically significant abnormal findings.
  • Normal FEV1/FVC ratio, defined as any value above 0.7 or above the lower 5th percentile of normal AND FEV1 >80% of predicted or above the lower 5th percentile of normal.
  • Pulse oximetry 02 saturation ≥95% in room air.
  • Negative test result for COVID-19 within 7 days of Day 1 AND concurrent with local hospital policy:
  • A nasopharyngeal swab tested with the ID NOW COVID-19 assay (Abbot). OR
  • A negative RNA-based test result of an oropharyngeal or nasopharyngeal swab or saliva sample performed according to CLIA/CLEP.
  • Females of child-bearing potential must be non-pregnant, non-lactating, have a negative urine pregnancy test at screening, and agree to use an acceptable form of birth control for 200 days after the last administration of the study drug. Females are considered of non-childbearing potential if they are postmenopausal (last menstrual period at least 1 year before screening) or have been surgically sterilized (documented hysterectomy, tubal ligation, or bilateral oophorectomy) for at least 6 months at screening.
  • Willing to comply with protocol-defined procedures and complete all study visits.
  • Willing to use the Inhalation System and exhale through the nose.
  • Adequate venous access in the left or right arm to allow collection of required blood samples.
  • Participant understands and communicates in English.
  • Serum Potassium level ≥3.5 mEq/L, Serum Magnesium level ≥1.5 mg/dL, and Serum Calcium ≥8.5 mg/dL.

Exclusion criteria

  • Any self-reported symptoms of influenza-like or COVID-19-like illness in the 14 days preceding the study visit: Fever >101.4 °F, sore throat, nasal congestion, post-nasal discharge, shortness of breath, gastrointestinal distress, wheezing, cough, headache, or fatigue.
  • Any history of diagnosed chronic lung disease, including but not limited to asthma or chronic obstructive lung disease.
  • Symptoms of seasonal allergies or use of any drugs for seasonal allergies or any inhaled (oral/nasal) drugs in the 2 weeks prior to Day 1. Mild seasonal allergy symptoms that have not altered sleep or activity patterns nor required use of over-the-counter (OTC) or prescription medications are allowed.
  • Any close contact exposure in the past 28 days to a person who was diagnosed as having COVID-19, with or without laboratory confirmation, during that close contact exposure or in the ensuing 14 days OR a similar encounter with a person who was determined to have suspected COVID-19, defined by that person being ordered to enter isolation for that indication by a medical authority. Close contact is defined as being within approximately 6 feet of a COVID-19 case for a prolonged (>10 minutes) period of time and can occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 patient OR having direct contact with infectious secretions of a COVID-19 patient (e.g., being coughed on), if such contact occurred while not wearing the recommended personal protective equipment for that type of contact [e.g., gowns, gloves, N95 respirator (or equivalent), eye protection].
  • Any participant with a history of SARS-CoV-2 infection that was confirmed by testing or diagnosed without testing within 4 weeks preceding Day 1. If infection occurred more than 4 weeks prior, candidates may be enrolled if they meet the rest of the eligibility criteria.
  • Any participant with a history severe respiratory illness that required hospitalization in the 60 days preceding Day 1 OR any participant with a history severe respiratory illness that required hospitalization in the preceding 120 days without full recovery.
  • Participation in another clinical study that involved treatment with an investigational product or device within 30 days of screening or during the study.
  • Participants with a known history of human immunodeficiency virus (HIV) infection.
  • Known, active hepatitis A, B, or C infection.
  • History of bronchospasm in response to use of an inhalation device.
  • Use of any prescription medication (except oral contraceptives) during the 30 days prior to study dosing that may affect drug absorption, metabolism and excretion, prolong the QTc interval, affect drug efficacy, or increase the risk of adverse reactions, unless approved by the Principal Investigator.
  • Use of any OTC product, herbal product, diet aid, hormone supplement, etc., within 7 days prior to dosing unless approved by the Principal Investigator.
  • Unwilling or unable to provide written informed consent.
  • Any known hypersensitivity to quinolines (e.g., hydroxychloroquine, chloroquine, primaquine, quinine) or known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or any contraindication to oral hydroxychloroquine.
  • Known retinopathy, fundus disease, or macular disease.
  • Diagnosis of long QT Syndrome.
  • Smoking of tobacco or non-tobacco substances, or vaping, within the last 6 months.
  • Severe obesity (body mass index [BMI] ≥35 kg/m2).

Treatment and study plan

Aerolized Hydroxychloroquine Sulfate

Drug

sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.

Other names: AHCQ

Placebo

Other

The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.

Primary outcomes

  1. Incidences of treatment-emergent adverse events (TEAEs) as assessed by TGSHAAV (September 2007) or CTCAE version 5.0

    Time frame: after treatment (Day 1) through to Day 30

    TEAEs (defined as AEs with onset after study drug administration or existing AEs that worsen in severity after study drug administration)

  2. Change from baseline in clinical laboratory test results for CBC with differential

    Time frame: Screening and Day 8

    Blood sample collected for CBC with differential will be assessed from baseline (at screening)

  3. Incidence of abnormal laboratory test results for CBC with differential at Screening

    Time frame: Screening

    Screening blood sample collected for CBC with differential, counting the number of abnormal clinical tests

  4. Incidence of abnormal laboratory test results for CBC with differential - Day 8

    Time frame: Day 8

    Day 8 blood sample collected for CBC with differential

  5. Changes from baseline for blood glucose

    Time frame: Screening and Day 1

    Blood sample collected for blood glucose and measured with a glucometer

  6. Incidence of abnormal laboratory test results for chemistry -Screening

    Time frame: Screening

    Blood sample collected for chemistry panel (albumin, total protein, ALP, ALT, AST, direct and indirect bilirubin, GGT, BUN, creatinine, glucose, bicarbonate, calcium, chloride, magnesium, phosphate, potassium, sodium, and LDH)

  7. Incidence of abnormal laboratory tests results for chemistry - Day 8

    Time frame: Day 8

    Blood sample collected for chemistry panel (albumin, total protein, ALP, ALT, AST, direct and indirect bilirubin, GGT, BUN, creatinine, glucose, bicarbonate, calcium, chloride, magnesium, phosphate, potassium, sodium, and LDH)

  8. Incidence of abnormal laboratory tests results for urinalysis - Screening

    Time frame: Screening

    Collection of urine sample to test pH, specific gravity, protein, glucose, ketones, urobilinogen, bilirubin, leukocyte esterase, squamous cells, epithelial cells, clarity, bacteria, blood

  9. Incidence of abnormal laboratory tests results for urinalysis- Day 8

    Time frame: Day 8

    Collection of urine sample to test pH, specific gravity, protein, glucose, ketones, urobilinogen, bilirubin, leukocyte esterase, squamous cells, epithelial cells, clarity, bacteria, blood

  10. Changes in vital signs from baseline (pre-dose) - respiratory rate

    Time frame: Screening, Day 1, Day 2 and Day 8

    The Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials (September 2007) (TGSHAAV) will be used as the primary criteria for assessment of clinical abnormalities. Mild (17-20 breaths per minute) to Potentially Life Threatening (intubation)

  11. Changes in vital signs from baseline (pre-dose)- temperature

    Time frame: Screening, Day 1, Day 2 and Day 8

    Oral temperature

  12. Changes in vital signs from baseline (pre-dose) - seated blood pressure

    Time frame: Screening, Day 1, Day 2 and Day 8

    Systolic and diastolic blood pressure

  13. Changes in vital signs from baseline (pre-dose) - pulse

    Time frame: Screening, Day 1, Day 2 and Day 8

    Heart rate measure by radial pulse rate (beats/min)

  14. Changes in vital signs from baseline (pre-dose) - O2 saturation

    Time frame: Screening, Day 1, Day 2 and Day 8

    O2 saturation (%), measured by pulse oximeter. Graded as per TGSHAAV (September 2007) from Moderate (pulse oximeter <92%) to Potentially Life Threatening (Life-threatening airway compromise; urgent intervention indicated)

  15. Incidence of abnormal and physical examinations findings during Screening- general appearance

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  16. Incidence of abnormal and physical examinations findings on Day 1 - general appearance

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  17. Incidence of abnormal and physical examinations findings on Day 2- general appearance

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  18. Incidence of abnormal and physical examinations findings on Day 8- general appearance

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  19. Incidence of abnormal and physical examinations findings during Screening- neurological

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  20. Incidence of abnormal and physical examinations findings on Day 1- neurological

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  21. Incidence of abnormal and physical examinations findings on Day 2- neurological

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  22. Incidence of abnormal and physical examinations findings on Day 8- neurological

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  23. Incidence of abnormal and physical examinations findings during Screening - heart/cardiovascular

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  24. Incidence of abnormal and physical examinations findings on Day 1 - heart/cardiovascular

    Time frame: Day 1 (pre-dose, within 3 hours of dose)

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  25. Incidence of abnormal and physical examinations findings on Day 2 - heart/cardiovascular

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  26. Incidence of abnormal and physical examinations findings on Day 8 - heart/cardiovascular

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  27. Incidence of abnormal and physical examinations findings during Screening - lungs

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  28. Incidence of abnormal and physical examinations findings on Day 1 - lungs

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  29. Incidence of abnormal and physical examinations findings on Day 2 - lungs

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  30. Incidence of abnormal and physical examinations findings on Day 8 - lungs

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  31. Incidence of abnormal and physical examinations findings during Screening- abdomen

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  32. Incidence of abnormal and physical examinations findings on Day 1 - abdomen

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  33. Incidence of abnormal and physical examinations findings on Day 2- abdomen

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  34. Incidence of abnormal and physical examinations findings on Day 8- abdomen

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  35. Incidence of abnormal and physical examinations findings during screening- endocrine

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  36. Incidence of abnormal and physical examinations findings on Day 1 - endocrine

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  37. Incidence of abnormal and physical examinations findings on Day 2- endocrine

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  38. Incidence of abnormal and physical examinations findings on Day 8- endocrine

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  39. Incidence of abnormal and physical examinations findings during Screening- extremities

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  40. Incidence of abnormal and physical examinations findings on Day 1- extremities

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  41. Incidence of abnormal and physical examinations findings on Day 2- extremities

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  42. Incidence of abnormal and physical examinations findings on Day 8- extremities

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  43. Incidence of abnormal and physical examinations findings during Screening- lymphatic

    Time frame: Screening

    Physical exam by clinician. A directed physical examination will be conducted

  44. Incidence of abnormal and physical examinations findings on Day 1- lymphatic

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  45. Incidence of abnormal and physical examinations findings on Day 2 - lymphatic

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  46. Incidence of abnormal and physical examinations findings on Day 8- lymphatic

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  47. Incidence of abnormal and physical examinations findings during screening - skin

    Time frame: Screening

    A directed physical examination will be conducted

  48. Incidence of abnormal and physical examinations findings on Day 1 - skin

    Time frame: Day 1

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  49. Incidence of abnormal and physical examinations findings on Day 2 - skin

    Time frame: Day 2

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  50. Incidence of abnormal and physical examinations findings on Day 8 - skin

    Time frame: Day 8

    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  51. Changes from baseline for pulmonary function tests (PFTs) - FEV1

    Time frame: Screening, Day 1 at pre-dose (within 25 minutes of dose) and at +15 minutes, +1, +3 and +6 hours after study treatment, and on Day 2 and Day 8.

    Pulmonary function testing and recording of FEV1, both actual and percent predicted

  52. Changes from baseline for pulmonary function tests (PFTs) - FVC

    Time frame: Screening, Day 1 at pre-dose (within 25 minutes of dose) and at +15 minutes, +1, +3 and +6 hours after study treatment, and on Day 2 and Day 8.

    Pulmonary function testing and recording of FVC, , both actual and percent predicted

  53. Changes from baseline for pulmonary function tests (PFTs) - FEV1/FVC

    Time frame: creening, Day 1 at pre-dose (within 25 minutes of dose) and at +15 minutes, +1, +3 and +6 hours after study treatment, and on Day 2 and Day 8.

    Pulmonary function testing and recording of FEV1/FVC

  54. Changes from baseline for ECG readings - QT interval

    Time frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8.

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval (msec) will be the assessment parameter.

  55. Changes from baseline for ECG readings - QTcB Interval

    Time frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8.

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QTcB interval (msec) will be the assessment parameter.

  56. Changes from baseline for ECG readings - QRS duration

    Time frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8.

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QRS duration (msec) will be the assessment parameter.

  57. Changes from baseline for ECG readings - PR interval

    Time frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8.

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG PR interval (msec) will be the assessment parameter.

  58. Changes from baseline for ECG readings - heart rate

    Time frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8.

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG heart rate (beats/min) will be the assessment parameter.

  59. Incidence of abnormal ECG - Screening

    Time frame: Screening

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.

  60. Incidence of abnormal ECG- Day 1

    Time frame: Day 1 pre-dose (within 3 hours of dose) and +2 and +6 hours

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.

  61. Incidence of abnormal ECG - Day 2

    Time frame: Days 2

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.

  62. Incidence of abnormal ECG - Day 8

    Time frame: Days 8.

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.

Secondary outcomes

  1. HCQ concentration in whole blood versus time profiles

    Time frame: Day 1 pre-dose (time 0) and +2, +3, +5, and +15 minutes after dose, and also +1, +2, +4 and +6 hours post-dose completion. Day 2 (+24±4 hours post dose) and Day 8.

    Blood samples for PK analysis will be collected via indwelling catheter or via direct venipuncture.

Sponsors and collaborators

Lead sponsor

Pulmoquine Therapeutics, Inc

Industry

Collaborators

  • Rockefeller University

Registry information

Official study title

A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 8, 2020
Registry last updated
Oct 8, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.